[Federal Register Volume 63, Number 150 (Wednesday, August 5, 1998)]
[Notices]
[Page 41879]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-20869]
=======================================================================
-----------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Issuer Delisting; Notice of Application to Withdraw From Listing
and Registration; (ImmuCell Corporation, Common Stock, $.10 Par Value;
Common Stock Purchase Rights) File No. 1-12934
July 30, 1998.
ImmuCell Corporation (``Company'') has filed an application with
the Securities and Exchange Commission (``Commission''), pursuant to
Section 12(d) of the Securities Exchange Act of 1934 (``Act'') and Rule
12d2-2(d) promulgated thereunder, to withdraw the above specified
securities (collectively ``Securities'') from listing and registration
on the Boston Stock Exchange, Inc. (``BSE'' or ``Exchange'').
The reasons cited in the application for withdrawing the Securities
from listing and registration include the following:
The Common Stock, $.10 Par Value, of the Company (``Common
Stock''), currently is listed for trading on the Nasdaq SmallCap Market
and the BSE. The Common Stock Purchase Rights are transferred with, and
only with, the Common Stock and may not be separately transferred
unless certain triggering events occur in the future.
The Company has complied with the instructions of the BSE by filing
with the Exchange a letter signed by the Company's President and CEO
and the Company's Chief Financial Officer, Treasurer and Secretary
authorizing the withdrawal of its Securities from listing on the BSE
and setting forth in detail the reasons for the proposed withdrawal and
the facts in support thereof.
In making the decision to withdraw its Securities from listing and
registration on the BSE, the Company considered the costs and expenses
attendant on maintaining the dual listing of its Securities on the
Nasdaq SmallCal Market and the BSE. Given the extremely low trading
volume experiences on the BSE over the prior several years, the Company
does not see any advantage in maintaining the dual listing of its
Securities and believes that the costs outweigh the benefits of
maintaining the listing on the BSE.
By letter dated July 6, 1998, the Exchange informed the Company
that it would not object to the withdrawal of the Company's Securities
from listing and registration on the BSE.
The withdrawal from listing of the Company's Securities from the
BSE shall have no effect upon the continued listing of such Securities
on the Nasdaq SmallCap Market.
By reason of Section 12(g) of the Act and the rules thereunder, the
Company shall continue to be obligated to file reports under Section 13
of the Act with the Commission and the Nasdaq SmallCap Market.
Any interested person may, on or before August 20, 1998, submit by
letter to the Secretary of the Securities and Exchange Commission, 450
Fifth Street, NW., Washington, DC 20549, facts bearing upon whether the
application has been made in accordance with the rules of the Exchange
and what terms, if any, should be imposed by the Commission for the
protection of investors. The Commission, based on the information
submitted to it, will issue an order granting the application after the
date mentioned above, unless the Commission determines to order a
hearing on the matter.
For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.
Jonathan G. Katz,
Secretary.
[FR Doc. 98-20869 Filed 8-4-98; 8:45 am]
BILLING CODE 8010-01-M
